Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Insulet

Stocks Close Higher as Market Sentiment Improves

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.54%. US stocks settled moderately higher on Friday due to an improvement in market sentiment....

Barchart

Stocks Continue to Rebound in the Afternoon Trading Session

The S&P 500 Index ($SPX ) (SPY ) is up +0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.75%. US stocks today are trading higher. Akamai Technologies is up more than +10% after reporting...

Barchart

Stocks Waver on Mixed Corporate News

The S&P 500 Index ($SPX ) (SPY ) is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. US stocks today are trading between modest gains and losses due to mixed corporate news....

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Undercut by Mixed Corporate News

The S&P 500 Index ($SPX ) (SPY ) is down -0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. US stocks today are being undercut by mixed corporate news. Insulet is down more than...

Barchart

Insulet's Q2 2024 Earnings: What to Expect

Insulet will release its second-quarter earnings next month, and analysts anticipate double-digit bottom-line growth.

Barchart

Insulet Forecasts Weak Revenue Growth, Shares Drop

Insulet Corporation faces challenges as it forecasts weak revenue growth due to market competition and supply chain issues.

Top News

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga

5 Analysts Have This to Say About Insulet

Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:

Benzinga

4 Analysts Have This to Say About Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Benzinga

Looking Into Insulet's Return On Capital Employed

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

Expert Ratings for Insulet

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

Benzinga

Recap: Insulet Q1 Earnings

Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 73.91%, reporting an EPS of $0.4 versus an estimate of $0.23.

Benzinga

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…

Benzinga

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

Insulet Corp's (NASDAQ: PODD)

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Insulet Q4 Earnings

Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 31.25%, reporting an EPS of $0.42 versus an estimate of $0.32.

Benzinga

Expert Ratings For Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Benzinga

FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above

The

Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX

Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares down premarket. Citigroup downgraded

1 2

People

Collins

185 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.